TPI provides its latest research note on Avacta Group Plc (AVCT.L).

Avacta has announced that it will launch a high-performance Affimer research enzyme-linked immunosorbent assay (‘ELISA’) test in order to support global research efforts into the coronavirus that causes COVID-19.

While the Group’s primary focus remains on its much larger, saliva-based coronavirus antigen rapid test opportunity being developed with Cytiva, its management has also recognised that there are thousands of researchers around the world in need of such a powerful, standardised laboratory ‘research tool’ to support their studies of the virus and develop solutions by which to combat the Pandemic.

Given that the ELISA ‘kit’ uses the same Affimer reagents as those incorporated in the rapid saliva test, there is a direct read-across from the performance of the ELISA to what is likely to be seen from the clinical validation of the rapid saliva test.

The development of the ELISA test is a by-product of the rapid saliva test, yet the scale of the potential long-term market opportunity identified is considered large enough for Avacta to now be having active discussions with potential OEM partners and distributors globally.

Read More

We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to Avacta Group Plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.

The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

Copyright © 2019 Turner Pope Investments (TPI) Limited, all rights reserved.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
Share via
Copy link
Malcare WordPress Security